Respiratory Inhalers Market Scope Overview and Regional Trends By 2026 | AstraZeneca, Beximco Pharmaceuticals, Boehringer Ingelheim GmbH, Cipla, GlaxoSmithKline, Koninklijke Philips N.V., Merck

Chronic respiratory diseases are the group of chronic diseases which affect airways, lungs and the other parts of respiratory system. Chronic respiratory disease include asthma and respiratory allergies, Chronic Obstructive Pulmonary Disease (COPD), Occupational Lung Diseases, Sleep Apnea Syndrome and Pulmonary Hypertension. However 70% chronic respiratory disease are asthma and chronic obstructive pulmonary disease. In 2012, globally, 1 billion people are affected with chronic respiratory disease and account for 7% of all global deaths with addition 1.4 million lung cancer deaths annually. Tuberculosis is considered as one of the communicable lung disease and in 2012, 1.3 million people died of tuberculosis and 8.6 million new cases were yet to be treated.
The respiratory inhalers market is expected to gain steady traction in the foreseeable future as the product is available in various designs and can be used by any age group individual. Manufacturers are focused on reducing production costs and increasing profitability to sustain the market demand.

Request For Sample Copy Of This Research Report : https://www.coherentmarketinsights.com/insight/request-sample/227

Market Dynamics
Factors such as rising prevalence of asthma, chronic obstructive respiratory disease and other respiratory diseases propel the respiratory inhalers market globally. However, drawbacks such as lack of a single effective inhaler devices, adverse effects and difficulties faced during drug inhalation, lack of skilled pulmonologist, higher price of inhaler devices are factors hindering respiratory inhalers market growth.
People suffering from respiratory disorders are now switching towards combinational therapies which is associated with benefits such as increased efficacy and easy reimbursement policies. Opting for combination therapies becomes tough for the individuals who have complex indications of respiratory disease. High preference of combination therapies such as triple combination therapy for chronic obstructive pulmonary disease (COPD) patients is expected to drive growth of the global respiratory inhaler market over the forecast period.

Detailed Segmentation:
• Global Respiratory Inhalers Market, By Product Type:
◦ Dry Powder Inhalers
▪ Single Unit Dose
▪ Multi Dose
▪ Multi-Unit Dose
◦ Metered Dose Inhalers
◦ Nebulizers
▪ Compressed
▪ Mesh
▪ Ultrasonic
Growth in respiratory inhalers market on the backdrop of product launches and Technological Advancements

For instance:
• In 2017, Cipla launched Synchrobreathe, a revolutionary inhaler that will bring great relief to millions of South Africans with obstructive airway diseases (OAD) such as asthma
• Smart inhalers have embedded sensors with bluetooth technology. These devices also come up with touchscreens, audio visual medication reminders along with additional advantages such as mobile application connectivity, customized user interface options, real time analysis through cloud based portals through researchers and clinicians. In September, 2017, Adherium received approval from the U.S Food and Drug Administration (FDA) for its SmartTouch inhaler monitoring device to be used with AstraZeneca’s Symbiocort aerosol inhaler.
• In October, 2017, United Therapeutics Corporation received U.S. FDA approval for a new inhalation device TD-300/A, for the use with Tyvaso (treprostinil) inhalation solution to treat patient with pulmonary arterial hypertension. The device aid patient compliance and provides ease of use. It will also reduce the rate of therapy discontinuation associated with the current nebulizer.

Increasing number of research collaborations is expected to improve the time-to-market of highly effective and advanced products. Some of the major players involved in global respiratory inhalers market are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

Request For Customization of This Research Report: https://www.coherentmarketinsights.com/insight/request-customization/227

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.